Ace Therapeutics announced the launch of its custom ocular modeling services, designed to accelerate advancements in ophthalmology research and enhance the discovery of therapeutic interventions. This groundbreaking service provides researchers with tailored models that closely mimic human ocular conditions, enabling more reliable results in preclinical studies.
As ophthalmological...
Ace Therapeutics, a preclinical CRO in psychiatry dedicated to offering comprehensive one-stop services, released the expansion of its research capabilities in the area of depression through the introduction of comprehensive depression-related behavior tests in its preclinical investigation processes. This integral development aims to enhance the understanding of depressive disorders and...
With a commitment to advancing new drug development for liver and gastrointestinal (GI) diseases, Ace Therapeutics proudly announces the launch of its custom disease model development services, which come with a complete range of research services from target discovery to predictive efficacy testing. This strategic addition to Ace Therapeutics’ portfolio not only enhances its service...
Ace Therapeutics is excited to announce the launch of its groundbreaking glaucoma gene therapy development services. This new initiative is set to advance research in glaucoma treatments, offering comprehensive support and innovation for researchers and pharmaceutical companies aiming to cure this pervasive eye disease.
Glaucoma is a group of eye conditions that damage the optic nerve,...
English
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt